Hexagen CV (benzalkonium chloride) / Turn Therap - LARVOL DELTA

Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19. (clinicaltrials.gov) - P2b; N=85; Completed; Sponsor: Turn Therapeutics

New P2b trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Turn Therapeutics Announces First Subjects Enrolled in Human Clinical Trial for the Treatment and Prevention of COVID-19 (Businesswire) - "Turn Therapeutics...announced enrollment of the first subjects in its COVID-19 treatment and prevention clinical trial.... Hexagen, will be administered intranasally...The company expects enrollment to be swift, with multiple patients and healthcare providers enrolled just today. An initial data readout is expected in early March 2021....This randomized, placebo-controlled trial will enroll approximately 100 mild to moderate COVID-19 patients and 50 healthcare workers across four leading hospitals in Panama."

Clinical data • Enrollment status • Infectious Disease • Novel Coronavirus Disease